Search
Enliven Therapeutics Inc
ELVNAdd to Watchlist
45.960USD
-0.550-1.18%
Market hours 09/30, 12:28（ET）
3.21BMarket Cap
LossP/E TTM
Enliven Therapeutics Inc (ELVN) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Enliven Therapeutics Inc in the past month.
Buy
5 Strong Buy
8 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
73.455USD+64.14%
ELVN Analyst Recommendation Trends
In the current month, ELVN has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ELVN average Analyst price target in the last month is 73.455.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
5
5
5
4
3
3
3
3
8
8
7
7
7
7
7
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
12
11
10
10
10
10
Financial Forecasting
Based on analysts' estimates, ELVN EPS is projected to reach -0.438 in FY2026Q3, following reported EPS of -0.491 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.38
-0.46
-0.40
-0.44
-0.53
Actual
-0.48
-0.38
-0.49
--
--
Surprise
-26.10%
+18.69%
-23.28%
--
--
FAQs
What is Enliven Therapeutics Inc's expected revenue for the next quarter?
Enliven Therapeutics Inc's expected revenue is 8.33K.
What is Enliven Therapeutics Inc's price target?
Analysts forecast that Enliven Therapeutics Inc's price target is USD 38.00, with the highest forecast at USD 52.00 and the lowest forecast at USD 33.00.
How have Enliven Therapeutics IncELVN's recent earnings per share performed?
The market expectation was USD -0.49, while Enliven Therapeutics IncELVN's earnings per share (EPS) for the previous quarter was USD -0.38. EPS for the next quarter is expected at USD -0.44.
What is the analyst rating for Enliven Therapeutics Inc?
Based on the ratings of Enliven Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.